title: The selective D₃ receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preference.
abstract: We examined the effect of acute administration of the selective D3 receptor antagonist SB-277011A on morphine-triggered reactivation of cocaine-induced conditioned place preference (CPP) in adult male Sprague-Dawley rats. Repeated pairing of animals with 15 mg/kg i.p. of cocaine HCl or vehicle to cue-specific CPP chambers produced a significant CPP response compared to animals paired only with vehicle in both chambers. Expression of the CPP response to cocaine was then extinguished by repeatedly giving the animals vehicle injections in the cocaine-paired chambers. The magnitude of the CPP response after extinction was not significantly different from that of animals paired only with vehicle. Expression of the extinguished CPP response was reactivated by acute administration of 5 mg/kg i.p. of morphine but not by vehicle. Acute administration of 6 or 12 mg/kg i.p. (but not 3 mg/kg) of SB-277011A significantly attenuated morphine-triggered reactivation of the cocaine-induced CPP. SB-277011A itself (12 mg/kg i.p.) did not reactivate the extinguished CPP response. Overall, SB-277011A decreases the incentive motivational actions of morphine. The present findings suggest that central D₃ dopamine receptors are involved in relapse to cocaine-seeking behavior, that a final common neural mechanism exists to mediate the incentive motivational effects of psychostimulants and opiates, and that selective dopamine D₃ receptor antagonists constitute promising compounds for treating addiction.
authors: Psychology Department, Furman University, Greenville, South Carolina 29613, USA.
authors: Onarae V
authors: OV
authors: Rice
authors: Christian A
authors: CA
authors: Heidbreder
authors: Eliot L
authors: EL
authors: Gardner
authors: Charles D
authors: CD
authors: Schonhar
authors: Charles R
authors: CR
authors: Ashby
mesh_terms: D000818:Animals; D003042:Cocaine / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects*; D003463:Cues; D018492:Dopamine Antagonists / Q000494:pharmacology*; D058999:Drug-Seeking Behavior; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009042:Motivation / Q000187:drug effects; D009570:Nitriles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D050637:Receptors, Dopamine D3 / Q000037:antagonists & inhibitors*; D044005:Tetrahydroisoquinolines / Q000494:pharmacology*
chemical_list: D018492:Dopamine Antagonists; D009570:Nitriles; D050637:Receptors, Dopamine D3; C409982:SB 277011; D044005:Tetrahydroisoquinolines; D009020:Morphine; D003042:Cocaine
references: Brain Res Rev. 2009 Mar;59(2):253-77
references: 18762212
references: Eur J Pharmacol. 2011 Jun 1;659(2-3):187-92
references: 21466803
references: Br J Pharmacol. 2004 Oct;143(3):343-50
references: 15339858
references: Psychopharmacology (Berl). 2000 Dec;153(1):31-43
references: 11255927
references: Behav Brain Res. 2000 Oct;115(1):39-47
references: 10996406
references: J Neurosci. 1996 Mar 1;16(5):1957-63
references: 8774462
references: Behav Brain Res. 2002 Oct 17;136(1):151-60
references: 12385800
references: Neural Plast. 2003;10(4):279-90
references: 15152982
references: J Neurosci. 2000 Dec 1;20(23):8677-84
references: 11102473
references: Pharmacol Biochem Behav. 1984 Jun;20(6):917-23
references: 6463075
references: Synapse. 2003 Jun 1;48(3):154-6
references: 12645041
references: Pharmacol Biochem Behav. 1999 Oct;64(2):327-36
references: 10515309
references: CNS Neurol Disord Drug Targets. 2006 Feb;5(1):25-43
references: 16613552
references: Pharmacol Rev. 2002 Mar;54(1):1-42
references: 11870259
references: Addict Biol. 2007 Mar;12(1):35-50
references: 17407496
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):118-123
references: 12420155
references: J Neurosci. 2002 Apr 1;22(7):2916-25
references: 11923456
references: J Neurosci. 2002 Nov 1;22(21):9595-603
references: 12417684
references: Int J Neuropsychopharmacol. 2010 Sep;13(8):1035-51
references: 20663270
references: Neuropsychopharmacology. 2006 Jul;31(7):1393-405
references: 16205781
references: Science. 1996 Mar 15;271(5255):1586-9
references: 8599115
references: J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65
references: 10945872
references: Neuropsychopharmacology. 2003 Jul;28(7):1272-80
references: 12700694
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):3-20
references: 12402102
references: J Med Chem. 2000 May 4;43(9):1878-85
references: 10794704
references: Psychopharmacology (Berl). 1995 Jun;119(3):334-41
references: 7675970
references: Pharmacol Biochem Behav. 2000 Jul;66(3):559-61
references: 10899370
references: Neuropsychopharmacology. 2002 Jan;26(1):18-26
references: 11751029
references: Neurosci Biobehav Rev. 2006;30(2):215-38
references: 16099045
references: N Engl J Med. 1996 Apr 11;334(15):965-72
references: 8596599
references: Psychopharmacology (Berl). 1999 Apr;143(3):254-60
references: 10353427
references: CNS Drug Rev. 2007 Summer;13(2):240-59
references: 17627675
references: Brain Res Brain Res Rev. 2000 Aug;33(1):13-33
references: 10967352
references: Psychopharmacology (Berl). 2004 Sep;175(2):154-62
references: 14985920
references: Pharmacol Biochem Behav. 2004 Oct;79(2):331-42
references: 15501310
references: Science. 1997 Oct 3;278(5335):66-70
references: 9311929
references: J Pharmacol Exp Ther. 2000 Aug;294(2):680-7
references: 10900248
references: Neurotox Res. 2008 Oct;14(2-3):169-83
references: 19073424
references: Behav Brain Res. 2002 Nov 15;136(2):389-97
references: 12429400
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):216-221
references: 12536264
references: Synapse. 2005 Jul;57(1):17-28
references: 15858839
references: Behav Pharmacol. 2005 Jul;16(4):253-9
references: 15961965
references: Adv Psychosom Med. 2011;30:22-60
references: 21508625
references: Psychopharmacology (Berl). 2006 Nov;189(1):1-16
references: 17019567
references: Eur J Pharmacol. 2005 Dec 5;526(1-3):36-50
references: 16289451
references: Neuropharmacology. 2009 Mar;56(4):752-60
references: 19136017
references: Neuropsychopharmacology. 2002 Jan;26(1):130-4
references: 11751040
references: J Neurosci. 2000 Aug 1;20(15):RC89
references: 10899176
references: Synapse. 2012 Jan;66(1):85-7
references: 21905128
references: Eur J Neurosci. 2005 Jun;21(12):3427-38
references: 16026480
references: Brain Res. 1988 Aug 9;457(2):287-94
references: 3219557
references: Ann N Y Acad Sci. 2010 Feb;1187:4-34
references: 20201845
references: Eur J Neurosci. 1998 Nov;10(11):3565-71
references: 9824469
references: Curr Drug Abuse Rev. 2008 Nov;1(3):303-27
references: 19430578
references: Behav Brain Res. 2004 Jun 4;152(1):157-61
references: 15135979
references: Neuroreport. 2000 Aug 21;11(12):2781-4
references: 10976962
references: Brain Res Brain Res Rev. 2005 Jul;49(1):77-105
references: 15960988
references: Psychopharmacology (Berl). 1990;100(3):355-60
references: 2315433
references: Addict Biol. 2007 Sep;12(3-4):227-462
references: 17678505
references: Curr Psychiatry Rep. 2008 Oct;10(5):377-84
references: 18803910
references: J Psychopharmacol. 2011 Feb;25(2):263-73
references: 20142301
references: Pharmacol Ther. 2005 Oct;108(1):18-58
references: 16183393
references: Psychopharmacology (Berl). 1996 Jun;125(4):385-91
references: 8826544
references: Psychopharmacology (Berl). 2004 Oct;176(1):57-65
references: 15083257